MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...

Compounded versions could make up as much as 40% of the semaglutide market, said Novo Nordisk CEO Lars Fruergaard Jorgensen ...

Patients with diabetes who take semaglutide are at increased risk for NAION compared with patients who do not use GLP-1 RAs to control their blood sugar, a new study finds.

Body weight loss was associated with increased odds of type 2 diabetes remission in a dose-dependent manner among patients with obesity.

The average weight for women in the U.S. is 170.8 pounds, and the average height is 5 feet, 3 inches tall. These are ...

Is the era of sourcing cheaper weight loss drugs from the internet over? High demand for GLP-1 agonists — prescription drugs ...

Taking medications like Ozempic and Wegovy may lead to more hair loss than other weight loss drugs, new research found.

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

Despite the current downward trend of NVO, it is a good stock to add to one's portfolio for long-term gains due to strong ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, ...